Clinical and experimental evaluation of cefoxitin therapy.
30 patients were treated with i.v. cefoxitin (4-8 g/day), of which 20 had documented infections which included endocarditis (5), lung abscess (4), empyema (4), liver and subhepatic abscess (3), osteomyelitis (3), and pancreatic abscess (1). 14 patients had infections caused by anaerobic bacteria and 5 had endocarditis due to aerobic organisms. All but 2 patients with osteomyelitis of the mandible were cured. Adverse reactions were noted in 7 patients, mostly due to drug fever and leukocytosis; one had Coombs'-positive hemolytic anemia. The average serum cefoxitin levels were 24, 16, 12, and 4 microgram/ml at 1, 2, 3 and 4 h, respectively, and the average serum/pleural fluid ratio was 1:0.5 +/- 0.25. All anaerobic and aerobic isolates except one strain of Bacteroides fragilis were susceptible to cefoxitin at less than or equal to 32 microgram/ml. The concentration of cefoxitin in the tissues was measured in 8 rabbits; it was 4 +/- 1 microgram/ml in the heart and 2 +/- 0.5 microgram/ml in the femur and mandibular tissue, suggesting that the lack of response in cases of osteomyelitis could be due to inadequate antibiotic concentration in the bone. Our study suggests that cefoxitin can be used in the treatment of anaerobic infections and endocarditis due to susceptible organisms.
D000038:Abscess / Q000188:drug therapy; D000328:Adult; D000818:Animals; D001424:Bacterial Infections / Q000188:drug therapy*; D001431:Bacteriological Techniques; D002440:Cefoxitin / Q000378:metabolism / Q000627:therapeutic use*; D002511:Cephalosporins / Q000627:therapeutic use*; D004341:Drug Evaluation; D004653:Empyema / Q000188:drug therapy; D004697:Endocarditis, Bacterial / Q000188:drug therapy; D005260:Female; D006801:Humans; D008100:Liver Abscess / Q000188:drug therapy; D008169:Lung Abscess / Q000188:drug therapy; D008297:Male; D010019:Osteomyelitis / Q000188:drug therapy; D010195:Pancreatitis / Q000188:drug therapy; D011817:Rabbits; D014018:Tissue Distribution
D002511:Cephalosporins; D002440:Cefoxitin